<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01604928</url>
  </required_header>
  <id_info>
    <org_study_id>178-CL-008</org_study_id>
    <nct_id>NCT01604928</nct_id>
  </id_info>
  <brief_title>Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder</brief_title>
  <acronym>Blossom</acronym>
  <official_title>A Randomized, Double-blind, Parallel Group, Proof of Concept Study of YM178 in Comparison With Placebo and Tolterodine in Patients With Symptomatic Overactive Bladder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Europe B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is intended to test efficacy, safety and tolerability of two doses of YM178 against
      placebo and tolterodine to treat patients with symptoms of over active bladder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multinational, multicenter, double-blind, double-dummy,

      randomized, parallel group, placebo and active controlled phase II proof-of concept study.
      Patients are enrolled into a single-blind, 2-week placebo run in

      period after which they are randomized to 4 weeks of double-blind

      treatment with YM178 (low dose and high dose), placebo or tolterodine. Subsequently patients
      will be followed for an additional 2 weeks

      with single-blind placebo treatment. There are 6 visits in total: visit 1 at

      enrolment, visit 2 (baseline) after the 2-week placebo run-in, visits 3, 4 and 5

      after 1, 2 and 4 weeks of double-blind treatment respectively, and visit 6

      after a 2-week follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in mean number of micturitions per 24 hours</measure>
    <time_frame>Baseline and 4 weeks (end of treatment)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean number of urgency episodes/24 hours</measure>
    <time_frame>Baseline and 4 weeks (end of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean volume voided per micturition</measure>
    <time_frame>Baseline and 4 weeks (end of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean number of urge incontinence episodes/24 hours</measure>
    <time_frame>Baseline and 4 weeks (end of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean number of incontinence episodes/24 hours</measure>
    <time_frame>Baseline and 4 weeks (end of treatment)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">260</enrollment>
  <condition>Urinary Bladder, Overactive</condition>
  <arm_group>
    <arm_group_label>YM178 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YM178 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tolterodine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YM178</intervention_name>
    <description>Oral</description>
    <arm_group_label>YM178 Dose 2</arm_group_label>
    <arm_group_label>YM178 Dose 1</arm_group_label>
    <other_name>mirabegron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tolterodine</intervention_name>
    <description>Oral</description>
    <arm_group_label>Tolterodine</arm_group_label>
    <other_name>Detrusitol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is willing and able to complete the micturition diary correctly.

          -  Symptoms of overactive bladder (urinary frequency and urgency with or without
             incontinence) for ≥ 3 months

        At randomization:

          -  Patient must experience frequency of micturition on average ≥ 8 times per 24-hour
             period during the 3-day micturition diary period

          -  Patient must experience at least 3 episodes of urgency (grade 3 or 4) with or without
             incontinence, during the 3-day micturition diary period

        Exclusion Criteria:

          -  Pregnant women or women who intend to become pregnant during the study or women of
             childbearing potential who are sexually active and practicing an unreliable method of
             birth control or will be lactating during the study. Reliable contraceptive methods
             are intra-uterine devices, contraceptive pills of combination type, hormonal implants,
             contraceptive patches and injectable contraceptives

          -  Clinically significant outflow obstruction (at the discretion of the investigator)

          -  Significant post void residual volume (PVR&gt;200ml)

          -  Significant stress incontinence or mixed stress/urge incontinence where stress is the
             predominant factor as determined by the investigator (for female patients confirmed by
             a cough provocation test)

          -  Patients with a neurological cause for abnormal detrusor activity

          -  Diabetic neuropathy

          -  Evidence of a symptomatic urinary tract infection, chronic inflammation such as
             interstitial cystitis, bladder stones, previous pelvic radiation therapy or previous
             or current malignant disease of the pelvic organs

          -  Uncontrolled narrow angle glaucoma, urinary or gastric retention, colitis ulcerosa,
             toxic megacolon, myasthenia gravis or any other medical condition which in the opinion
             of the investigator makes the use of anticholinergics contra-indicated

          -  Non-drug treatment including electrostimulation therapy

        (a bladder training program or pelvic floor exercises which started more than 1 month prior
        to entry into the study can be continued)

          -  Use of medications intended to treat urinary incontinence or listed in Appendix 1 Part
             A. Part B lists medications that are restricted but accepted under certain conditions

          -  Known or suspected hypersensitivity to tolterodine, other anticholinergics,
             ß-adrenoceptor agonists, or lactose or any of the other inactive ingredients

          -  Any clinically significant cardiovascular complication including CVA, recent
             myocardial infarction and uncontrolled hypertension, indicated by a sitting systolic
             blood pressure ≥ 180 mmHg and/or diastolic blood pressure ≥ 110 mmHg

          -  Any clinically significant condition, which in the opinion of the investigator makes
             the patient unsuitable for the trial

          -  Participation in any clinical trial within 30 (90 in the UK) days prior to
             randomization

          -  Employees of the sponsor, third parties associated with the study, or the study site

        At randomization:

          -  Patient who did not complete the micturition diary according to the instructions

          -  Average total daily urine volume &gt; 3000 ml as recorded in the micturition diary

          -  Clinically significant elevation of serum creatinine or liver enzymes as evidenced by
             creatinine &gt;150 mmol/L, ASAT or ALAT &gt; 2x upper limit of normal range (ULN), γ-GT &gt; 3x
             ULN and/or abnormal serum total bilirubin (as assessed in visit 1 samples or
             alternative sampling within 4 weeks prior to visit 1)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Study Manager</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site: 12</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 13</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 11</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 10</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 25</name>
      <address>
        <city>Melnik</city>
        <zip>276 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 22</name>
      <address>
        <city>Prague</city>
        <zip>128 08</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 24</name>
      <address>
        <city>Prague</city>
        <zip>140 59</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 20</name>
      <address>
        <city>Prague</city>
        <zip>180 81</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 21</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>40001</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 23</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>401 13</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 32</name>
      <address>
        <city>Bad Ems</city>
        <zip>56130</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 30</name>
      <address>
        <city>Emmendingen</city>
        <zip>79312</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 35</name>
      <address>
        <city>Frankfurt</city>
        <zip>60326</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 34</name>
      <address>
        <city>Hagenow</city>
        <zip>19230</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 33</name>
      <address>
        <city>Hamburg</city>
        <zip>20253</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 36</name>
      <address>
        <city>Koblenz</city>
        <zip>56068</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 31</name>
      <address>
        <city>Trier</city>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 42</name>
      <address>
        <city>Alzira-Valencia</city>
        <zip>46600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 40</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 43</name>
      <address>
        <city>Miranda de Ebro</city>
        <zip>09200</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 55</name>
      <address>
        <city>Gotenburg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 53</name>
      <address>
        <city>Linkoping</city>
        <zip>582 24</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 50</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 51</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 52</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 64</name>
      <address>
        <city>Bimingham</city>
        <zip>B15 2TG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 62</name>
      <address>
        <city>London</city>
        <zip>N19 5LW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 63</name>
      <address>
        <city>London</city>
        <zip>W1P 7PN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 60</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 61</name>
      <address>
        <city>Swansea</city>
        <zip>SA6 6NL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=194</url>
    <description>Link to results on Astellas Clinical Study Results website</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2012</study_first_submitted>
  <study_first_submitted_qc>May 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2012</study_first_posted>
  <last_update_submitted>February 14, 2017</last_update_submitted>
  <last_update_submitted_qc>February 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Overactive Bladder</keyword>
  <keyword>YM178</keyword>
  <keyword>Mirabegron</keyword>
  <keyword>Frequency</keyword>
  <keyword>Urinary urge incontinence</keyword>
  <keyword>Urgency</keyword>
  <keyword>Urinary incontinence</keyword>
  <keyword>Micturition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirabegron</mesh_term>
    <mesh_term>Tolterodine Tartrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Details of the IPD sharing plan for this study can be found at www.clinicalstudydatarequest.com.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

